Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp (EHC) reported that Chief Accounting Officer Andrew L. Price sold Encompass Health Common Stock in a non-derivative transaction. On 2026-08-31, he sold 5,211 shares at $120.93 per share in an open market or private transaction. Following this sale, he directly holds 69,483 shares of Encompass Health Common Stock. The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.
For Encompass Health Corp (EHC), EVP, General Counsel & Secretary John Patrick Darby exercised 4,858 non-qualified stock options on 2026-08-31 at an exercise price of $35.06 per share, acquiring an equal number of Encompass Health common shares, and on the same date sold 4,858 shares at $121.09 per share. The option exercise price and option share amount were adjusted under the company’s 2016 Omnibus Performance Incentive Plan to reflect the spin-off distribution of Enhabit, Inc. The filing’s Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan.
Encompass Health Corp (EHC) has a notice of proposed sale under Rule 144 for shares held for the account of officer John Patrick Darby. The filing covers a proposed sale of 4,858 shares of common stock, to be effected through UBS Financial Services Inc. and associated with a stock option exercise, with an estimated aggregate market value of $588,255.71. The notice also reports Encompass Health common shares outstanding of 98,653,384 and discloses that Darby sold 8,906 shares of common stock over the prior three months for proceeds of $1,121,700.
Encompass Health Corporation (EHC) has filed an automatic shelf registration statement on Form S-3, allowing it to offer, from time to time, common stock, preferred stock, warrants, debt securities and guarantees of debt securities by certain subsidiaries. Proceeds may be used for general corporate purposes, including debt repayment, share repurchases, acquisitions, capital spending and working capital.
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States. As of June 30, 2026, it operated 176 hospitals in 39 states and Puerto Rico. For the six months ended June 30, 2026, the obligor group generated $2,065.1 million in total net operating revenues and $229.1 million in net income.
As of June 30, 2026, the obligor group reported total current assets of $671.4 million, total noncurrent assets of $4,399.9 million and long‑term debt of $2,537.8 million. The company is authorized to issue 200,000,000 shares of common stock; 98,788,107 common shares were outstanding and no preferred shares were outstanding as of that date.
T. Rowe Price Associates, Inc. reports beneficial ownership of 5,056,225 shares of Encompass Health Corp common stock, representing 5.1% of the class. The firm reports sole voting power over 4,897,333 shares and sole dispositive power over 5,056,225 shares, with no shared voting or dispositive power.
T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
Encompass Health Corporation completed a private issuance and sale of $100 million aggregate principal amount of 5.875% Senior Notes due 2034, guaranteed by certain subsidiaries. The notes were sold at 98.75% of principal, generating approximately $96.9 million in net proceeds after initial purchasers’ discounts and estimated expenses.
The company used the net proceeds, together with cash on hand, to repay a portion of the outstanding amounts under its revolving credit facility. These new notes are an additional issuance under the existing May 29, 2026 indenture, where $500,000,000 of identical 5.875% Senior Notes due 2034 are already outstanding. The new and existing notes form a single class under the indenture and rank pari passu.
Encompass Health Corp executive Douglas E. Coltharp, EVP & Chief Financial Officer, reported selling 18,869 shares of Encompass Health common stock on 2026-08-10 in a sale classified as an open market or private transaction at a weighted average price of $125.38 per share, with individual prices ranging from $125.03 to $125.69. Following this transaction, he directly holds 50,508 shares and also reports indirect holdings through irrevocable trusts and a spouse.
Encompass Health Corp President & CEO Mark J. Tarr reported two open-market sales of Encompass Health common stock on 2026-08-10. He sold 171,569 shares at a weighted average price of $125.46 and 1,579 shares at a weighted average price of $126.06, with each sale executed in multiple transactions within specified price ranges described in the footnotes. Post-transaction share holdings are not reported in this filing.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported selling 8,906 shares of Encompass Health common stock on 2026-08-10 in an open-market or private transaction. The weighted average sale price was $125.95 per share, across multiple trades between $125.94 and $126.04, leaving him with 75,041 shares held directly after the sale.